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On behalf of the scientists and surgeons of one of the big-
gest orthopedic institutes in Italy, located in Milan, we feel
the urge to share our position about the recent warnings
on the use of anti-inflammatory drugs (NSAIDs) in this
coronavirus “era.” Similarly to the antihypertensive drugs
angiotensin-converting enzyme (ACE) inhibitors, angio-
tensin receptor blockers (ARBs), and beta blockers, and
the oral antidiabetic drugs thiazolidinediones, some author
have suggested that NSAIDs, particularly Ibuprofen, may
induce increased sensitivity to more severe clinical fea-
tures in coronavirus (Covid-19) infection.
NSAIDs are widely used worldwide. In musculoskel-
etal medicine, they keep under control osteoarthritis,
tendinopathies, bursitis, muscle soreness, radicular pain,
and others. In Italy, about 12 millions of adults have
osteoarthritis or rheumatoid arthritis, a number esti-
mated to grow substantially in the next years [1]. More-
over, an extensive increase of orthopedic surgeries in
both developed and developing countries, the low cost
of drugs, and the progressive rise of the geriatric popula-
tion have contributed to the growth of global NSAIDs
use. According to the Italian Medicines Agency (AIFA),
in 2018 the defined daily doses (DDDs) per 1000 inhabi-
tants per day was 18.6 [2].
The warning about the possible role of NSAIDs in wors-
ening the severity of Covid-19 infection was very powerful
because it was spread by a representative of the national
medical authority of one of the European countries strongly
interested by this pandemic. The warning also suggested to
the population already under anti-inflammatory drugs to
ask their general practitioners for advice, unleashing a wave
of panic among the population, especially through social
media. Other official communications by the national
health systems and emergency management agency (EMA)
[3] attempted to bring back calm and rationality, with poor
results.
The effects of this warning has been very deleterious on
our patients, especially on those who need to use these
drugs for long periods for their medical conditions:
NSAIDs allow these patients to lead a good quality of life,
although we acknowledge that the prolonged use of these
drugs may cause side effects, including kidney failure, liver
failure, gastric ulcers, asthma attacks, heart and circulatory
problems, and a partial immune depression [4].
Being based in Milan, we, more than others, are dir-
ectly experiencing the devastating effects of this pan-
demic. We have been ready, and we still are now, to take
any useful measures to reduce its impact on our popula-
tion, without underestimating any possible new scientific
information. Nevertheless, albeit in the midst of a gen-
eral intellectual and emotional confusion, we try to
maintain our scientific judgment, and would like to
underline the danger of unproven and unfounded infor-
mation, especially when spread out through mass and
social media, which directly reach the general population
without any filter.
The current body of scientific literature reports just a
few articles analyzing the relationship between exposure
to NSAIDs and possible complications in patients with
pneumonia. A recent article investigated whether expos-
ure to NSAIDs prior to hospital admission among patients
suffering from community-acquired pneumonia (CAP)
was associated with the development of pleural complica-
tions or a lung abscess. NSAIDs intake was independently
associated with the development of pleuroparenchymal
complications (odds ratio = 2.57 [1.02–6.64], p = 0.049).
Nevertheless, given the lack of consistent results about the
direct effect of NSAIDs on the immunological response
and the lack of controlled randomized studies in human,
the authors could not conclude a direct effect of NSAIDs
in the development of the complications of CAP [5].
Surely, in addition to the supposed interfering effect of
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NSAIDs with responses mediated by the prostaglandin
and leukotriene pathways, NSAIDs, together with other
antipyretic and analgesic medications, can be responsible
for later presentation of symptoms or underestimation of
the severity of the disease, both leading to a delayed diag-
nosis and possible worse prognosis. A particular role in
exacerbating the Covid-19 infection seems to have been
assigned to Ibuprofen [6]. In diabetic rats, this chemical
has induced an over-expression of ACE2 that we now
know might be associated, theoretically, to an increase in
susceptibility to Covid-19 infection [7]. However, the ori-
ginal purpose of the study was different, and this observa-
tion should therefore be verified in a more specific ad hoc
experimental model. In addition, it is unclear how this
study in animals with a metabolic disorder would translate
to human medicine.
Despite the common global interest in preventing our
patients from suffering the most serious consequences
of this new infection, it would be dangerous to stop
some of these drugs based on not confirmed data. The
effects of such suspension could certainly worsen the
conditions of some patients, adding a supplementary
burden on our health providers who are already over-
whelmed by this enormous number of serious Covid-19
cases.
Physicians may consider to replace the molecule indi-
cated to be “most vile,” Ibuprofen, with a similar one
while waiting for more definitive data. In general, and
not only in these pandemic times, we agree that NSAIDs
should be taken only when strictly necessary, at the low-
est effective dose for the shortest possible period, pos-
sibly under a medical guidance and not as a self-
medication. Therefore, when indicated, we are suggest-
ing that our patients use drugs with less severe adverse
effects, such as paracetamol (i.e. acetaminophen), point-
ing in any case out that, in this period, other NSAIDs
and paracetamol could also mask the pyrexial signs of
COVID-19, resulting in a delayed diagnosis of the
infection.
The risks deriving from the use of NSAIDS and the
Covid-19 infection should be analyzed from two differ-
ent perspectives: (i) risks related to exposure to NSAIDs
before the patient has been infected and (ii) risks related
to the use of a drug during the COVID-19 infection.
These two scenarios are dramatically different, and pose
different scientific questions, which should be addressed
by adequate studies. In other words, would the adminis-
tration of this drug before being infected causes the
same effect of taking it during the infection period? We
also have to distinguish between the possible increase in
susceptibility to the virus, especially in terms of severity,
and the increase in aberrant host response.
Patients continue to produce the virus for weeks: the
treatment of infected patients with immunosuppressant
such as corticosteroids might increase the amount of
virus replication [8]. Therefore, we certainly agree with
interrupting any administration of immunosuppressant
drugs in patients with confirmed or suspect diagnosis of
Covid-19 infection. Further, given the concerns of a link
between NSAIDs and both respiratory and cardiovascu-
lar adverse effects in conditions similar to Covid-19 in-
fections, we do not recommend the regular NSAID use
as the first line option for managing the symptoms of
Covid-19 [9]. On the other hand, given the reliability of
the current data, we are oriented not to modify the
therapeutic protocols of non-infected chronic patients
until we have new evidence indicating the opportunity or
indeed the necessity to do so.
As recently stated [10], there is no time to carry on
randomized controlled studies following the usual stan-
dards we are used to. In this emergency, the scientific
community should leave the usual schemes, and propose
instead practical research programs. This does not imply
poor quality studies, but the best studies we can perform
in such a short time frame, where any second is crucial
to save many lives. Social separation, although effective,
is only aimed to slow down the growing curve of infec-
tion: the discovery of new targeted chemicals will deter-
mine whether a patient will develop complications or
make a full recovery. Similarly, the discovery of possible
dangerous interactions between some classes of drugs
and Covid-19 is what will prevent a further worsening of
this infection in some patients, reducing the number of
serious cases.
Following the invitation by EMA for timely epidemio-
logical studies to provide adequate evidences on the ef-
fects of NSAIDS on prognosis of Covid-19 infection, our
institute is about to start an epidemiologic study using our
pathology registries [11]. In particular, the total joint re-
placement registries report data of thousands of patients,
including their drug consumptions. Since Lombardy
alone, a region of about 10 million people, as of today ac-
counts for more than 51,234 positive cases (roughly 4% of
the worldwide cases), we believe that our data will give
specific information about the supposed risks of the use of
different classes of drugs and the Covid-19 infection. Our
registry records will be matched with the regional registry
of Covid-19 cases to retrieve any possible correspondence
between drug assumption and susceptibility to pulmonary
complications. The results of the study, providing either
convincing positive or negative evidence of association,
will add an important piece of information to clinical care
as the coronavirus pandemic continues.
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